Free Trial
NASDAQ:CMND

Clearmind Medicine (CMND) Stock Price, News & Analysis

Clearmind Medicine logo
$1.02 +0.04 (+4.08%)
Closing price 04/25/2025 03:55 PM Eastern
Extended Trading
$1.00 -0.03 (-2.45%)
As of 04/25/2025 07:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Clearmind Medicine Stock (NASDAQ:CMND)

Key Stats

Today's Range
$0.95
$1.02
50-Day Range
$0.92
$1.33
52-Week Range
$0.85
$2.30
Volume
77,265 shs
Average Volume
1.09 million shs
Market Capitalization
$4.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Clearmind Medicine Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
17th Percentile Overall Score

CMND MarketRank™: 

Clearmind Medicine scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Clearmind Medicine.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Clearmind Medicine is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Clearmind Medicine is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Clearmind Medicine has a P/B Ratio of 1.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Clearmind Medicine's valuation and earnings.
  • Percentage of Shares Shorted

    6.19% of the float of Clearmind Medicine has been sold short.
  • Short Interest Ratio / Days to Cover

    Clearmind Medicine has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Clearmind Medicine has recently decreased by 5.19%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Clearmind Medicine does not currently pay a dividend.

  • Dividend Growth

    Clearmind Medicine does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.19% of the float of Clearmind Medicine has been sold short.
  • Short Interest Ratio / Days to Cover

    Clearmind Medicine has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Clearmind Medicine has recently decreased by 5.19%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Clearmind Medicine has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Clearmind Medicine this week, compared to 1 article on an average week.
  • MarketBeat Follows

    1 people have added Clearmind Medicine to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Clearmind Medicine insiders have not sold or bought any company stock.

  • Percentage Held by Institutions

    96.05% of the stock of Clearmind Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Clearmind Medicine's insider trading history.
Receive CMND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clearmind Medicine and its competitors with MarketBeat's FREE daily newsletter.

CMND Stock News Headlines

The first casualty of the 2025 trade war
The headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim Plaehn reveals how the 2025 trade war is quietly eroding dividend income — and which U.S.-focused stocks are still raising payouts.
Psychedelic: Clearmind completes clinical site initiations for AUD trial
Clearmind Medicine completes initiation of AUD Phase I/IIa trial
See More Headlines

CMND Stock Analysis - Frequently Asked Questions

Clearmind Medicine's stock was trading at $1.38 at the beginning of 2025. Since then, CMND stock has decreased by 26.1% and is now trading at $1.02.
View the best growth stocks for 2025 here
.

Clearmind Medicine Inc. (NASDAQ:CMND) announced its quarterly earnings results on Thursday, March, 13th. The company reported ($0.24) earnings per share for the quarter.

Shares of Clearmind Medicine reverse split before market open on Tuesday, November 28th 2023. The 1-30 reverse split was announced on Tuesday, November 28th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Clearmind Medicine (CMND) raised $9 million in an initial public offering on Tuesday, November 15th 2022. The company issued 1,300,000 shares at a price of $6.00-$8.00 per share. Aegis Capital Corp. acted as the underwriter for the IPO.

Shares of CMND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Clearmind Medicine investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET), Meta Platforms (META), AppLovin (APP) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
3/13/2025
Today
4/25/2025
Next Earnings (Estimated)
6/12/2025
Fiscal Year End
10/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CMND
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-5,260,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.73 per share
Price / Book
1.40

Miscellaneous

Free Float
N/A
Market Cap
$4.35 million
Optionable
Not Optionable
Beta
0.94
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:CMND) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners